Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Study uncovers why lupus patients have weaker response to COVID-19 vaccines

A recent study by Emory University researchers provides new insights into why the mRNA vaccines developed to fight COVID-19 in 2021 are less effective in patients with autoimmune diseases.

16 Jan 2025

T-DM1 reduces long-term risk of death in HER2-positive breast cancer patients

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and improved survival compared to trastuzumab alone, according to the final results of the phase 3 KATHERINE clinical trial led by researchers from the University of Pittsburgh and UPMC Hillman Cancer Center.

16 Jan 2025

Tiny vesicles offer powerful new approach for cancer treatment

A new twist on a decades-old anticancer strategy has shown powerful effects against multiple cancer types in a preclinical study from researchers in the Perelman School of Medicine at the University of Pennsylvania.

16 Jan 2025

Unexpected viral reservoir: influenza A thrives in cattle mammary glands

Researchers uncover how influenza A virus infects dairy cattle, revealing the mammary gland's surprising role in viral replication and transmission through milk.

15 Jan 2025

Spear Bio secures FDA breakthrough device designation for its novel pTau 217 blood test, advancing scalable solutions for early Alzheimer's disease diagnosis

Spear Bio Inc., a biotechnology company pioneering next-generation ultra-sensitive immunoassays, today announced that its pTau 217 blood test has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA).

From Spear Bio 15 Jan 2025

CAR-NK cells offer safer, more accessible treatment for lymphoma

A new type of cell-based immunotherapy shows promise for B-cell lymphomas and - due to innovations in manufacturing - could make future cellular immunotherapies less expensive and more accessible to patients.

15 Jan 2025

Sapio Sciences Announces Enhanced Capabilities for Chemistry, Immunogenicity, GMP and Molecular Biology

Sapio Sciences' Release 24.12 enhances lab informatics with improved GMP workflows and molecular biology features, driving efficiency and scientific discovery.

From Sapio Sciences 14 Jan 2025

T cells can completely prevent viral infections in humans

Scientists from Duke-NUS Medical School and the Singapore General Hospital have discovered that T cells-white blood cells that can destroy harmful pathogens-can completely prevent viral infection, to an extent previously thought only possible due to neutralizing antibodies.

10 Jan 2025

Research from second pig heart transplant provides new directions for xenotransplantation

Continuing significant advancements in the field of xenotransplantation, surgeon-scientists from the University of Maryland School of Medicine provided an extensive analysis on the second patient in the world to receive a genetically-modified pig organ.

9 Jan 2025

New molecule shows promise in protecting mice from influenza

Researchers at the University of Gothenburg, Sweden, in collaboration with colleagues in China, have discovered an antibody-like molecule that can protect mice from various influenza viruses.

9 Jan 2025

Single-dose malaria vaccine offers unprecedented 90% protection

Results from the malaria vaccine trial indicate that GA2 immunization provides significant protection, paving the way for more effective vaccination strategies.

8 Jan 2025

Early detection of breast cancer proven cost-effective for Canada's health care system

Cancer screening is key to saving patients' lives since an earlier stage diagnosis improves survival rates, decreases morbidity, and leads to less intensive treatments.

7 Jan 2025

Decades of research push cytomegalovirus vaccine closer to reality

Researchers review decades of progress in human cytomegalovirus (HCMV) vaccine development, emphasizing challenges, innovative platforms, and the critical need for effective prevention strategies.

6 Jan 2025

Scientists identify novel antibodies for fighting malaria

A novel class of antibodies that binds to a previously untargeted portion of the malaria parasite could lead to new prevention methods, according to a study from researchers at the National Institutes of Health (NIH) published today in Science.

3 Jan 2025

CDC study highlights growing tularemia threat in central U.S.

Tularemia cases in the U.S. rose by 56% from 2011 to 2022, with central states and American Indian communities most affected, highlighting diagnostic advancements and health disparities.

2 Jan 2025

Breakthrough in immunology: AbMAP’s novel approach to antibody modeling

Researchers developed AbMAP, a cutting-edge framework leveraging transfer learning to model antibody hypervariable regions, significantly improving design and immune repertoire analysis.

2 Jan 2025

Blood cells linked to long-lasting vaccine immunity

When children receive their second measles-mumps-rubella vaccine, around the time they start kindergarten, they gain protection against all three viruses for all or most of their lives.

2 Jan 2025

Immunocompromised adults show weaker response to RSV vaccines

Johns Hopkins Medicine researchers have shown that people 60 years or older with weakened immunity - primarily organ transplant recipients who take immunosuppressive medications to reduce the risk of rejection and others with immune system disorders - do not respond as strongly to vaccines against the respiratory syncytial virus (RSV) as people in the same age group with normal immune function.

30 Dec 2024

WHO TAG-CO-VAC reviews COVID-19 vaccine effectiveness and antigen composition

The WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) continues to closely monitor the genetic and antigenic evolution of SARS-CoV-2 variants, immune responses to SARS-CoV-2 infection and COVID-19 vaccination, and the performance of COVID-19 vaccines against circulating variants.

24 Dec 2024

New Optimer contract to develop bioanalytical tools for RNA therapy

Aptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces the signing of a new development contract with a rare disease biopharmaceutical company.

From Aptamer Group 23 Dec 2024